Definitive Contract 75F40123C00185
Award Date 9/25/23
Potential Completion Date 6/28/27
Potential Value $400K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost No Fee
Place of Performance
Australia
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a firm-fixed-price definitive contract awarded by the Food and Drug Administration (FDA), a civilian federal agency, to the Institute for Clinical Pharmacodynamics, Inc., a minority-owned for-profit organization based in Schenectady, New York. The $248,553.46 contract is for the development of modernized susceptibility guidance for the antibiotic nitrofurantoin using a dynamic urinary tract in vitro infection model and pharmacometric approaches. This award is part of the FDA's Broad...
- The Food and Drug Administration awarded a $554.8K definitive contract on September 16, 2021, to The University of Auckland Research Office to develop in-vitro tools designed to simulate the chewing of pharmaceutical opioid drug products. This firm fixed-price contract, which carries an ultimate completion date of March 31, 2025, supports FDA's regulatory science mission by advancing methodologies that evaluate how opioid medications behave under physiological conditions relevant to human...
- The Food and Drug Administration (FDA) awarded a $4,935,108 definitive contract to the Commonwealth Scientific and Industrial Research Organisation (CSIRO), a non-profit research organization based in Australia. The contract is for a scientific research study entitled "Strengthening COVID-19 Animal Models and Regulatory Science Using a Systems Biology Approach." This contract was awarded under the FDA's Broad Agency Announcement for Advanced Regulatory Science, which aims to...
- The Food and Drug Administration awarded a $400,000 firm fixed-price contract to the Regents of the University of Michigan on September 26, 2022, to advance regulatory science methodologies in drug development. Specifically, the contract supports the FDA's Broad Agency Announcement seeking research and development proposals across multiple areas of interest, with this award focused on advancing the science of in vitro studies, animal models, pharmacokinetic studies, and real-world evidence...
- The U.S. Food and Drug Administration (FDA) awarded a $687,062 firm-fixed-price contract to the University of Sydney, doing business as the International Clinical Trials Symposium, for the development of a laser-based testing platform for generic dry powders. This definitive contract has a completion date of September 20, 2025. The University of Sydney is a leading Australian educational institution that frequently receives federal contracts and grants from various U.S. government agencies,...
- This $399,991 federal contract was awarded by the U.S. Food and Drug Administration (FDA) to Midwestern University, a private, non-profit educational institution, to develop and validate population pharmacokinetic models for beta-lactam antibiotics used in critical care settings, specifically to guide treatment for patients with hospital-acquired pneumonia. The contract is a definitive, cost-no-fee contract with a completion date of September 29, 2025. This contract was issued under a Broad...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1.89 million delivery order to Pharmacology Discovery Services Taiwan, LTD. on July 15, 2024, for the development of murine models of urinary tract infections caused by antibiotic-resistant bacteria. This delivery order falls under the Pre-Clinical Models of Infectious Diseases indefinite-delivery/indefinite-quantity (IDIQ) contract vehicle, which carries a ceiling value of $146.3 million and extends through July...
- The Food and Drug Administration awarded a $307,205 cost-no-fee contract to The Johns Hopkins University under Broad Agency Announcement PMWP#173 to evaluate the impact of extended-infusion beta-lactam administration strategies on improving clinical outcomes and reducing the subsequent emergence of antimicrobial resistance. The contract was awarded through the Department of Health and Human Services' Fiscal Year 2021 FDA Broad Agency Announcement for Advanced Research and Development of...
- The Food and Drug Administration (FDA) awarded a definitive cost-no-fee contract valued at $1.09 million to the University of Texas at Austin on September 29, 2020, to investigate the effect of repeat unit ordering on the properties of melt-extruded poly(lactide-coglycolide)-based long-acting implants. The research, to be conducted at UT Austin's Austin, Texas facility, focuses on understanding how the molecular structure and sequencing of polymer repeat units influences the performance...
- The Department of Health and Human Services Food and Drug Administration awarded a definitive contract to Purdue University, an institution of higher education and research, to characterize the structure and interactions of carboxymaltose with an iron core. The $667,142.00 cost-no-fee contract, awarded on September 22, 2021, has a completion date of September 29, 2023. This contract is associated with the FDA's Broad Agency Announcement for Advanced Regulatory Science, which solicits research...